Core Viewpoint - Palvella Therapeutics is advancing its QTORIN™ 3.9% rapamycin anhydrous gel program to address the unmet medical need for treatments of angiokeratomas, a rare skin disease affecting over 50,000 patients in the U.S. [1][6] Company Developments - The company plans to initiate a Phase 2 trial for QTORIN rapamycin in the latter half of 2026, with a meeting scheduled with the FDA in early 2026 to discuss the study design [1][3][6] - CEO Wes Kaupinen expresses optimism about QTORIN rapamycin's potential to become the first FDA-approved therapy for angiokeratomas, as current treatment options are limited and often involve painful procedures [2][6] Financial Analysis - H.C. Wainwright upgraded Palvella's stock rating to "Buy" on September 25, 2025, raising the price target from $75 to $95, while Stifel Nicolaus set a price target of $80, indicating a potential increase of approximately 33.62% from the stock price at that time [4] - Despite a negative price-to-earnings (P/E) ratio of -26.45 and a negative enterprise value to operating cash flow ratio of -42.71, the company maintains a strong liquidity position with a current ratio of 7.67, indicating sufficient current assets to cover liabilities [5][6]
Palvella Therapeutics, Inc. Expands QTORIN™ 3.9% Rapamycin Program
Financial Modeling Prep·2025-09-25 22:00